Literature DB >> 8687505

Cytochrome P-450 expression in sudden infant death syndrome.

J M Treluyer1, G Cheron, M Sonnier, T Cresteil.   

Abstract

In the human liver, the major rise of the cytochrome P-450 isoform content occurs during the first months following birth (e.g., the high vulnerability period to sudden infant death syndrome (SIDS), a syndrome frequently associated with viral infection and drug hypersensitivity. We examined the expression of individual P-450 isoforms in liver samples collected postmortem from SIDS infants and compared values with those of control adults and children of the same age suffering from various pathologies. Hepatic microsomes were prepared and examined for their content in total P-450, the level of individual isoforms (CYP1A2, CYP2E1, CYP4A, CYP3A, and CYP2C) determined with specific antibodies and for their enzymatic activities. Total RNA was extracted and probed with several CYP cDNAs and oligomers. The overall hepatic P-450 content was not modified in SIDS infants. Among cytochrome P-450 isoforms, only CYP2C was markedly increased. This rise resulted from an accumulation of RNA encoding CYP2C and was associated with a stimulation of diazepam demethylation. The precocious expression of CYP2C in SIDS could result in a higher production of epoxyeicosatrienoic acids in the neonate, believed to act as relaxant of pulmonary smooth muscles. Its consequence might be the induction of fatal apnea in SIDS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687505     DOI: 10.1016/0006-2952(96)00253-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Chronic Intermittent Hypoxia Causes Lipid Peroxidation and Altered Phase 1 Drug Metabolizing Enzymes in the Neonatal Rat Liver.

Authors:  Charles Cai; Jacob V Aranda; Gloria B Valencia; Jiliu Xu; Kay D Beharry
Journal:  React Oxyg Species (Apex)       Date:  2017-05-01

Review 2.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

3.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

6.  Age-dependent pharmacokinetics of lansoprazole in neonates and infants.

Authors:  Weijiang Zhang; Michael Kukulka; Galen Witt; Debra Sutkowski-Markmann; Janine North; Stuart Atkinson
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

7.  Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.

Authors:  Jessica Mae Grindheim; Dario Nicetto; Greg Donahue; Kenneth S Zaret
Journal:  Gastroenterology       Date:  2019-01-25       Impact factor: 22.682

Review 8.  Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Authors:  Siavosh Naji-Talakar; Sheena Sharma; Leslie A Martin; Derek Barnhart; Bhagwat Prasad
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

Review 9.  Incorporating children's toxicokinetics into a risk framework.

Authors:  Gary Ginsberg; William Slikker; James Bruckner; Babasaheb Sonawane
Journal:  Environ Health Perspect       Date:  2004-02       Impact factor: 9.031

Review 10.  Establishment of metabolism and transport pathways in the rodent and human fetal liver.

Authors:  Jamie E Moscovitz; Lauren M Aleksunes
Journal:  Int J Mol Sci       Date:  2013-12-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.